Suraksha Diagnostic Limited has postponed its 21st Annual General Meeting (AGM), originally scheduled for Wednesday, September 02, 2026. The company notified the stock exchanges on August 10, 2026, stating that the meeting stands postponed to a future date due to certain unavoidable circumstances. This development impacts shareholders who were preparing to vote on agenda items at the upcoming assembly.

The intimation was issued pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It serves as a continuation of an earlier intimation letter dated May 21, 2026. The company emphasized that the revised date, time, and venue for the 21st AGM will be decided in accordance with the Companies Act, 2013, read with rules made thereunder, and the SEBI LODR Regulations, 2015. Once finalized, these details will be formally informed to the Stock Exchanges and shareholders.

Key Details of the Postponement

The communication was signed by Ritu Mittal, Joint Managing Director & CEO of Suraksha Diagnostic Limited. The company expressed regret for any inconvenience caused to shareholders on account of the postponement. No specific new date was provided in this filing; instead, the company committed to informing stakeholders when the schedule is finalized.

This procedural update ensures compliance with regulatory disclosure norms while managing shareholder expectations regarding the timing of the annual assembly. Investors are advised to monitor official communications from the company and the stock exchanges for further updates on the rescheduled AGM date.

Suraksha Diagnostic has closed its trading window for all designated persons and their immediate relatives effective Wednesday, 01 July 2026. This restriction will remain in force until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. The measure is in accordance with the Company's Code of Conduct for regulating, monitoring, and reporting of trading by insiders, as mandated by the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The closure has been communicated to all designated and connected persons to ensure compliance with insider trading norms. The specific date for the Board of Directors' meeting to consider and approve the financial results for the quarter ended 30 June 2026 will be intimated to the stock exchanges in due course.

Key Details

The information regarding the trading window closure and subsequent results declaration will be available on the company's official website.